Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
9.57
-0.48 (-4.78%)
At close: Jun 27, 2025, 4:00 PM
9.55
-0.02 (-0.21%)
After-hours: Jun 27, 2025, 7:11 PM EDT
Dyne Therapeutics Employees
Dyne Therapeutics had 191 employees as of December 31, 2024. The number of employees increased by 50 or 35.46% compared to the previous year.
Employees
191
Change (1Y)
50
Growth (1Y)
35.46%
Revenue / Employee
n/a
Profits / Employee
-$1,922,147
Market Cap
1.09B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 191 | 50 | 35.46% |
Dec 31, 2023 | 141 | 22 | 18.49% |
Dec 31, 2022 | 119 | 26 | 27.96% |
Dec 31, 2021 | 93 | 46 | 97.87% |
Dec 31, 2020 | 47 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
DYN News
- 4 days ago - Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - DYN - PRNewsWire
- 10 days ago - Dyne Therapeutics - Emergence As A Superior DM1 / DMD Player Warrants Rating Upgrade - Seeking Alpha
- 10 days ago - Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – DYN - Business Wire
- 11 days ago - Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting - GlobeNewsWire
- 11 days ago - Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET - GlobeNewsWire
- 23 days ago - Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress - GlobeNewsWire
- 7 weeks ago - Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy - GlobeNewsWire